ArticleScientific reports2020
SMRT sequencing of the full-length transcriptome of Odontotermes formosanus (Shiraki) under Serratia marcescens treatment.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- A comprehensive analysis of the defense responses of Odontotermes formosanus (Shiraki) provides insights into the changes during Serratia marcescens infection.BMC genomics · 2024Article
- Article
- Unraveling metagenomics through long-read sequencing: a comprehensive review.Journal of translational medicine · 2024Review
- SMRT Sequencing Technology Was Used to Construct theInsects · 2023Article
- The transcriptomic response ofFrontiers in cellular and infection microbiology · 2023Article
- Article
- Article
- Full-length SMRT transcriptome sequencing and microsatellite characterization in Paulownia catalpifolia.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Odontotermes formosanus (Shiraki) is an important pest in the world. Serratia marcescens have a high lethal effect on O. formosanus, but the specific insecticidal mechanisms of S. marcescens on O. formosanus are unclear, and the immune responses of O. formosanus to S. marcescens have not been clarified. At present, genetic database resources of O. formosanus are extremely scarce. Therefore, using O. formosanus workers infected by S. marcescens and the control as experimental materials, a full-length transcriptome was sequenced using the PacBio Sequel sequencing platform. A total of 10,364 isoforms were obtained as the final transcriptome. The unigenes were further annotated with the Nr, Swiss-Prot, EuKaryotic Orthologous Groups (KOG), Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) Ortholog public databases. In a comparison between the control group and a Serratia marcescens-infected group, a total of 259 differentially expressed genes (DEGs) were identified, including 132 upregulated and 127 downregulated genes. Pathway enrichment analysis indicated that the expression of the mitogen-activated protein kinase (MAPK) pathway, oxidative stress genes and the AMP-activated protein kinase (AMPK) pathway in O. formosanus may be associated with S. marcescens treatment. This research intensively studied O. formosanus at the high-throughput full-length transcriptome level, laying a foundation for further development of molecular markers and mining of target genes in this species and thereby promoting the biological control of O. formosanus. Furthermore, these results will be helpful to clarify the action mechanisms of S. marcescens on O. formosanus, and also explore the relationship between O. formosanus and S. marcescens. In addition, this study will identify the immune response of O. formosanus to S. marcescens, which will provide a theoretical foundation for the development of new immunosuppressants for O. formosanus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.